is tirzepatide semaglutide Semaglutide/Tirzepatide: Beyond Weight Loss: Shamsah Amersi, MD: OB-GYNs There is no one-size-fits-all approach

While evidence suggests GLP-1 receptor agonists have protective effects against arterial disease, the evidence specifically examining venous thrombosis risk is more limited, though no safety signals have emerged

After 48 weeks of treatment, participants receiving 8 mg and 12 mg doses experienced a mean body weight reduction of 22.8% and 24.2%, respectivelyan outcome comparable to bariatric surgery

A modest reduction of fasting plasma glucose levels was observed in mice with FATP2 gene ( Slc27a2 ) deletion (6)

The percent coefficient of variation (%CV), calculated as the standard deviation divided by the mean of a sample, was 20.4% and 24.1% for healthy control and FEP glutamate measurements, respectively, and 24.8% and 22.6% for healthy control and FEP GSH measurements, respectively (control vs

doi:10.1111/cns.13207 Hadtstein F, Vrolijk M

This can help reduce the risk of heart disease and complement the cardiovascular benefits of semaglutide